<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Hacker News: sourcinnamon</title><link>https://news.ycombinator.com/user?id=sourcinnamon</link><description>Hacker News RSS</description><docs>https://hnrss.org/</docs><generator>hnrss v2.1.1</generator><lastBuildDate>Thu, 24 Sep 2026 18:50:27 +0000</lastBuildDate><atom:link href="https://hnrss.org/user?id=sourcinnamon" rel="self" type="application/rss+xml"></atom:link><item><title><![CDATA[New comment by sourcinnamon in "Claude discovers a novel enzyme system with CRISPR-like repeats"]]></title><description><![CDATA[
<p>In addition to the other comment mentioning CAR-T therapies, we also have therapies based on tumor-infiltrating lymphocytes (TILs)<p><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma" rel="nofollow">https://www.cancer.gov/news-events/cancer-currents-blog/2024...</a><p><a href="https://jitc.bmj.com/content/8/2/e000848" rel="nofollow">https://jitc.bmj.com/content/8/2/e000848</a> (careful: Figure 1 can be very graphical, but it shows the huge positive impact of this therapy)<p>We also have therapies based on monoclonal recombinant antibodies conjugated with chemotherapeutics. Simply put, we can produce antibodies that are specific for markers present in the surface of cancer cells, and we can attach drugs that can kill those cells. The antibody part is what makes this type of therapy very effective (you target only cancer cells, and not healthy cells) and also very expensive.</p>
]]></description><pubDate>Wed, 23 Sep 2026 19:19:27 +0000</pubDate><link>https://news.ycombinator.com/item?id=49821134</link><dc:creator>sourcinnamon</dc:creator><comments>https://news.ycombinator.com/item?id=49821134</comments><guid isPermaLink="false">https://news.ycombinator.com/item?id=49821134</guid></item><item><title><![CDATA[New comment by sourcinnamon in "The spread of Christianity, from antiquity until today, on an animated map"]]></title><description><![CDATA[
<p>The allegedly lack of progress during the "Dark ages" is a narrative constructed later on, during the Illustration/Enlightenment era. Just to mention an example, alchemical research was verly prolific in that time, and it was the basis for what we now call chemistry and pharmacology.</p>
]]></description><pubDate>Fri, 22 May 2026 16:34:47 +0000</pubDate><link>https://news.ycombinator.com/item?id=48238202</link><dc:creator>sourcinnamon</dc:creator><comments>https://news.ycombinator.com/item?id=48238202</comments><guid isPermaLink="false">https://news.ycombinator.com/item?id=48238202</guid></item><item><title><![CDATA[New comment by sourcinnamon in "MIT: 20% drop in incoming graduate students"]]></title><description><![CDATA[
<p>I agree that completing a PhD under the time originally agreed may not be good, as you lose some of the learning opportunities that come with the apprenticeship (yes, it is) program.<p>However, taking more time than the standard length, whatever it is depending on the university or country where you are pursuing the title, is also something universities and specially PIs should be actively avoiding.<p>Maybe I have this view because I got mine in NL, where a PhD is a job with a defined length (4 years) and if you go over it, you don't get paid. So yes, it is an apprenticeship, but you should not be doing work for free in any case. Becoming an expert and the (relative) independence on how to do your research are of course selling points of the PhD, but a job is a job.</p>
]]></description><pubDate>Thu, 14 May 2026 18:19:05 +0000</pubDate><link>https://news.ycombinator.com/item?id=48139141</link><dc:creator>sourcinnamon</dc:creator><comments>https://news.ycombinator.com/item?id=48139141</comments><guid isPermaLink="false">https://news.ycombinator.com/item?id=48139141</guid></item></channel></rss>